secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001818331-24-000057
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance
--------------------------------------------------------------------------------

- Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).
- Adjusted net income $1.2M (first profitable quarter); GAAP net loss $8.3M.
- Adjusted gross margin 64%, up from 48% YoY.
- FY 2024 revenue guidance raised to $284–290M (prev. $255–265M).
- Cash use improved 88% YoY to $5.0M; $117.4M cash as of Sept. 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000057/0001818331-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000057/wgs-20241029.htm
  HTML page:      https://secwatch.observer/filing/0001818331-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer